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CMF (cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2,
ﬂuorouracil 600 mg/m2) in 19 women or FAC (ﬂuorouracil
500 mg/m2, doxorubicin 50 mg/m2, cyclophosphamide 500 mg/
m2) in 42 women. Alltogether 61 women were included into
study. Frequency and gradus of unwanted effects were measured
during ﬁve days after one arrival for the treatment. Neuthropenia
was measured by counting white blood cells 18–20 days after
chemotherapy. Diarrhoea, nausea and vomiting were graduated
by counting of number of episodes per day for ﬁve days after
each treatment. For each protocol the costs of treatment for
cytostatics as well as for treatment of unwanted effects and need
for prolonged hospitalisation were calculated. RESULTS: There
was a higher incidence of nausea, vomiting and neuthropenia in
FAC vs. CMF treatments (73.81%, 23.57%, 21.43% vs.
57.98%, 15.79%, 10.53%) and higher incidence of diarrhoea in
CMF vs. FAC treatments (5.68% vs. 2.38%). Anthracycline-
based protocols (FAC) caused greater severity of nausea, vomit-
ing and diarrhoea than CMF with equaly severe neuthropenia.
Drugs used for treatment of nausea, vomiting and neuthropenia
were setrons, corticosteroids and metoclopramide. The cost for
the one treatment episode for cytostatics were higher for FAC
(66.94 EU pre single dose, 401.64 EU for the whole cycle) than
for CMF (19,10 EU per single dose, 229.20 EU for whole cycle).
The costs of drugs used for the treatment of AEs were 13.20 EU/
patient/episode reciving CMF and 17.24 EU/patient/episode
reciving FAC protocol. CONCLUSIONS: CMF is safer and
cheaper than FAC protocol.
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COST-EFFECTIVENESS OF EXTENDED ADJUVANT
TREATMENT WITH LETROZOLE IN SWEDEN
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1Novartis Sweden,Täby, Sweden, 2Akademiska Hospital, Uppsala,
Sweden
OBJECTIVES: The MA17 trial showed that addition of letrozole
after 5 years tamoxifen was effective in further reducing the risk
of relapse in women with breast cancer. Recent data also indicate
that the cost of breast cancer relapse is much higher than previ-
ously shown, which has important implications for the beneﬁt of
adjuvant treatment. Further, the cost-effectiveness of adjuvant
treatment from a societal perspective and in the Nordic countries
is so far not extensively assessed. The objective of this study was
to assess cost-effectiveness of extending the adjuvant therapy in
Sweden, from a societal perspective. METHODS: Consequences
for a woman at the age of 62 years who have completed 5 years
tamoxifen treatment were assessed, from a societal and health
care perspective. Clinical data on risk of relapse and adverse
events were based on the MA17 trial. Costs, health utilities and
survival data were based on recent detailed Swedish data. A
reduction in relapse risk was extrapolated into a survival beneﬁt,
by assuming a higher mortality for patients with relapse.
RESULTS: The total societal cost for letrozole- and placebo-
treated patients were €7700 and €6300, respectively, a difference
of €1500. The difference in life-years and QALYs were 0.23 and
0.18, respectively, leading to costs of €6500 per life-years gained
and €8300 per QALY gained. The corresponding cost-
effectiveness ratios from a health care perspective were €10,500
per life-years gained and €13,400 per QALY gained. CONCLU-
SIONS: The study indicates that the incremental cost per QALY
gained for extended letrozole treatment in Sweden is low, and
hence indicates that money spent of extending the adjuvant treat-
ment with letrozole probably is money well spent in Sweden.
More long-term data on the overall survival gain would be
valuable to further validate the assumption used in the analysis.
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OBJECTIVES: To predict the expected incremental costs and
mean life-years associated with adding bevacizumab to
FOLFOX4 in the adjuvant treatment of patients with AJCC/
UICC stage III colon carcinoma following surgical resection.
METHODS: A three-health state (disease-free survival [DFS],
relapse/new occurrence of colon carcinoma, and death) Markov
model was used to explore the effects of adding one year of
adjuvant treatment with bevacizumab to the existing adjuvant
FOLFOX4 treatment regimen. Baseline DFS for FOLFOX4-
treated patients was based on published data from the MOSAIC
trial (André et al 2004). The relative risk reduction for bevaci-
zumab was based on protocol assumptions for the ongoing phase
III AVANT study. Outcomes included life-years, QALYs, direct
costs, and incremental cost-effectiveness ratios (ICERs) expressed
as costs per QALY or life-year gained. A life time horizon (40
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years) was used; after 8 years, patients were assumed to only be
at risk for death. Costs and outcomes were discounted at 3.5%
per annum. Sensitivity analyses were performed to identify inﬂu-
ential parameters in the model. RESULTS: Undiscounted mean
life expectancy for patients treated with FOLFOX4 was esti-
mated at 15.9 years. Assuming the addition of bevacizumab
reduces the risk of relapse by 23% in the ﬁrst 3 years after
surgery, as described in the protocol, and by 10% in the follow-
ing 5 years, mean survival was estimated to increase to 18.1 years
(10.8 to 12.1 years when discounted). The discounted ICER was
£19,939/life year gained. Sensitivity analysis showed that
assumptions relating to the magnitude of the relapse risk reduc-
tion and the duration of risk reduction were the most critical
determinants of the ICER. CONCLUSIONS: Addition of beva-
cizumab to FOLFOX4, the current standard regimen for patients
with stage III colon carcinoma, is expected to improve clinical
outcomes and to be a cost-effective treatment option from a UK
perspective.
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OBJECTIVES: The purpose of this study is to estimate the
cost-effectiveness (CE) of 1-year trastuzumab treatment versus
standard care (observation following standard adjuvant chemo-
therapy) in early stage breast cancer (eBC) patients in Portugal.
METHODS: A 5-state Markov model with annual transition
cycles was developed to estimate the long term health and eco-
nomic outcomes of eBC patients based on HERA clinical trial
results. The model included the following health states: disease
free survival, recurrence, metastasis, cardiac events and death.
The model assumes a hypothetical patient cohort similar to those
of HERA study. The evaluation assumes both the health care
payer and societal perspectives. Portuguese NHS resource use
and costs were estimated from a consensus experts panel and
published unit costs, respectively, including cancer therapy costs,
adverse cardiovascular events treatment costs, disease diagnosis
and management costs and indirect costs (time off of work).
Outcomes were discounted at 3% per annum. One-way sensitiv-
ity analysis was performed on the discount rate, quality of life
estimates and non-trastuzumab treatment costs. RESULTS:
Treatment with trastuzumab was estimated to increase dis-
counted life expectancy by 2.11 in years (14.95 vs 12,84) and
quality-adjusted life expectancy by 2.01 QALYs compared to
standard care. Direct and indirect costs were projected to be
€61.839 and €19,759 with trastuzumab and €40,559 and
€25.391 with standard of care. These results corresponded to
ICERs of €10,067 and €10,595 assuming direct costs only and of
€7789 and €7400 including indirect costs, per life year gained
(LYG) and per QALY gained, respectively. CONCLUSIONS: The
1-year trastuzumab use as adjuvant therapy in HER-2 positive
eBC patients improves survival and can be considered a cost
effective therapy with a high degree of certainty in the Portuguese
setting.
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OBJECTIVES: To obtain a Dutch cost-effectiveness estimate of
trastuzumab in early breast cancer, based on a previous UK
model-based cost-effectiveness analysis. Trastuzumab is a
humanized monoclonal antibody against the HER2-receptor
extracellular domain. METHODS: Following the model trans-
ferability assessment, required adjustments were made. In a
Markov cohort model, 1 year adjuvant trastuzumab therapy was
compared to observation. Model outcomes are life years,
quality-adjusted life years (QALYs), health care costs, and cost
of productivity loss. The cycle length is one year, the time
horizon is lifetime. UK prices were replaced by updated Dutch
unit prices. Clinical input data originated from the HERA-trial;
health utilities were obtained from literature. The impact of
parameter uncertainty was assessed using age subgroup analyses,
one-way sensitivity analyses and probabilistic sensitivity analy-
sis. Subsequently, we conducted expected value of perfect infor-
mation analyses. RESULTS: In The Netherlands, from a health
care perspective the ICER for trastuzumab for a 55 year old
patient was estimated at €19,463/QALY. From a societal per-
spective the ICER became €14,867. As expected, ICERs improve
with younger age. Sensitivity analyses showed that the ICER was
sensitive to the time horizon and the costs for the metastasic
health state. CONCLUSIONS: Overall the Dutch cost-
effectiveness estimate of trastuzumab for early stage breast
cancer can be well described and is well below the Dutch infor-
mal threshold of €80,000/QALY. For the base case analysis the
probability that the ICER is acceptable for thresholds above
€27.000/QALY is 1, indicating a probability of zero for a wrong
decision. Hence, for thresholds above €27,000 the expected
value of information is zero. This analysis provided an early
cost-effectiveness indication of trastuzumab in the adjuvant
setting in The Netherlands and has led to the provisional reim-
bursement. The transferability assessment is addressed in a sepa-
rate abstract.
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OBJECTIVES: Bevacizumab recently received a revised market-
ing authorisation for use in CRC that states “Bevacizumab in
combination with ﬂuoropyrimidine-based chemotherapy is indi-
cated for treatment of patients with metastatic carcinoma of the
colon or rectum”. This means that bevacizumab can be used in
combination with a wider choice of therapies than previously
allowed. This revised indication was based on the NO16966
phase III trial, which evaluated the efﬁcacy of bevacizumab
in combination with capecitabine + oxaliplatin (XELOX).
METHODS: A health state transition model was constructed to
estimate patient survival, stratiﬁed between progression-free sur-
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